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Wehave recently found that 2,5,6-trichloro- H~-D-ribofuranosyl)benzimidazole(TCRB) and the cor-
responding 2-bromo analog have better in vitro activities against HCMV than the clinically used agents gan-
ciclovir and foscarnet, These benzimidazole nucleosides act by a unique mechanism, however, their bio-
logical target has not been completely identified. As an approach to probing the target, we have designed
imidazo[4,S-b]quinoxaline nucleosides as linear dimensional analogs of the benzimidazole uucleosides to
study the spatial limitation of the binding site in the target enzyme. A convenient route was developed for
the synthesis of 2-substituted 6,7-dichloroimidazo[4,5-b]quinoxaiines involving a reaction of 2,3,6,7-
tetrachloroquinoxaliue with ammonia followed by a ring annulation as the key step. This furnished the ver-
satile heterocycle 6,7-dichloroimidazo[4,5-b]quinoxatin-2-one. Ribosylation of 2-substituted imidazo[4,5-
b]quinoxaiines was influenced by the functional group at the 2-position and the 2-one compound was found
to smoothly undergo ribosylation. The 2-one group of the nucleoside was converted into specifically se-
lected 2-substituted compounds. Evaluation of the compounds for activity against two herpesviruses and
for cytotoxicity showed they were less active and/or more cytotoxic than TCRB. We conclude therefore,
thai the binding pocket on the protein target of TCRB will tolerate some electronic and size changes.
INTRODUCTION
Human cytomegalovirus (HCMV) is a human herpes
virus which has a high order of genome sequence complex-
ity and a narrow host range.' Although HCMV is innocuous
in the immunocompetent individual, it is a significant patho-
gen in neonates and immunocompromised individuals' such
as bone marrow) and organ transplant' patients as well as in-
dividuals with acquired immune deficiency syndrome
(AIDS).5 Ganciclovir, toscamet and cidofovir are the only
drugs approved by the United States Food and Drug Ad-
ministration for the treatment of HCMV infections. How-
ever, all of them have poor bioavailability and side eflccts."
Moreover, HCMV strains resistant to ganciclovir and fos-
carnet have been reported.' Moreover, co-administration of
ganciclovir and zidovudinc (AZT) was found to cause syn-
ergistic toxicity both in vitro and in AIDS patients," Conse-
quently, there is a need for better, more potent and selective
antiviral drugs to treat HCMV infections.
Recently in our laboratory, a series of polyhalogenated
benzimidazole ribonucleosides were found to have potent
activity and high selectivity against human cytomegalovirus
(HCMV).9,lO The lead compounds 2,S,6-trichloro-I-(~-D­
ribofuranosyljbenzimidazole (TCRB, Ia) and 2-bromo-S,6-
dichloro-I-(~-D-ribofuranosyI)benzimidazole (BDCRB,
Ib) were more active and less cytotoxic than ganciclovir,
foscarnet, and the 2-unsubstituted benzimidazole ribonu-
cleoside DRB (If).9.11,12 Furthermore, both compounds
were found to act by a unique mechanism which does not in-
volve inhibition of DNA synthesis but does involve inhibi-
tion of DNA processing, 13 Beside TCRB, BDCRB, and the
related 2-isopropylamino-L-riboside analog of TCRB
(l263W94),14 derivatives with other substituents such as
benzylthio (Ic), cyclopropylamino (ld) and isopropylamino
(Le}, at the 2-position were also found to be active against
HCMV.10,14
In an effort to investigate the spatial limitations of the
binding site of the targeted enzyme to the heterocyclic agly-
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con of the benzimidazole ribonucleosides 1, we have syn-
thesized a series of imidazo]4,5-b]quinoline ribonu-
cleosides." These compounds were designed as linear di-
mensional analogs of 1 with an electron withdrawing pyri-
dine ring as the spacer. In that study, both the Nl (2) and the
N3 (3) isomers of the imidazo[4,5-b]quinoline ribonu-
cleosides were prepared to assess the possible effects of the
pyridine-spacer in addition to the spatial and electronic ef-
fects on the biological activities. It was found that, in gen-
eral, the Nl-isomers (2) were active against HCMV and had
some separation bSlween activity and toxicity whereas the
corresponding N}ffsomers (3) were either inactive or
showed no separation between activity and toxicity." These
results demonstrated that in addition to the designed spatial
and electronic effects, there must be other factors which
play an important role on the observed biological activity:
This difference in the biological activity, due to the use of a
pyridine ring as a spacer, should be the result of an inherent
structural difference between 2 and 3. The difference be-
tween 2 and 3 involves the different relative location of the
pyridine nitrogen. On one hand, this nitrogen offers the
possibility for an additional hydrogen-bonding site, and on
the other, generates different steric interactions between the
ribosyl moiety and the aglycon which could affect the most
favorable conformation of the nucleosides,
To continue our study on the linear dimensional ana-
logs of benzimidazole ribonucleosides with electron-with-
drawing spacers and to identify the factor(s) which causers)
the different antiviral activity observed between 2 and 3, a
series of imidazo]4,5-b]quinoxaline ribonucleosides (4)
was selected. These pyrazino-separated dimensional ana-
logs (4) have additional nitrogens in the spacer on either
side of the aglycon. This introduction of a pyrazine ring
system would have the same steric interaction between the
aglycone and the ribosyl moiety as proposed for 3 and the
RESULTS AND DISCUSSION
Chemistry
Using the same strategy as in the previous synthesis of
2 and 3, we selected a route in which the substituents at the
2-position of 4 would be generated from an appropriate in-
termediate in the final steps of the synthesis. The ribonu-
cleoside of 6,7-dichloroimidazo[4,5-b]quinolin-2-one (Sa)
was chosen as the immediate precursor since the compound
was expected to be fairly stable and contains a versatile
functional group at the 2-position. We elected to use
2,3,6,7-tetrachloroquinoxalincI 6 (5) as our starting material
for the synthesis of the heterocycle 6,7-dichloroimi-
dazo[4,5-b]quinoxalin-2-one (7). Compound 5 was con-
verted into 2,3-diamino-6,7-dichloroquinoxaline (6) by the
treatment of 5 with ammonia at 90 0 C. Compound 6 was
ring closed by using carbonyl diimidazole in toluene at re-
flux to give 7. Attempts to use urea for the conversion 17 of 6
to 7 failed, most likely due to the electron withdrawing ef-
fect of the two chloro substituents.
Although the synthesis of imidazo[4,5-b[quinoxalines
has been studied extensively, IS to the best of our knowledge
there have been no reports on the synthesis of imidazo[4,5-
b]quinoxaline nucleosides. The ribosylation of 7 was
achieved under Vorbruggen conditions. 19 When 7 was sily-
Iated with N,O-bis{trimethyJsilyJ)acetamide (BSA) fol-
lowed by the addition of I-O-acetyl-2,3,5-tri-O-benzoyl-~­
Dsribofuranose (TBAR) and trimethylsilyl trifluoromethyl-
sulfonate (TMSOTf), 6,7-dichloro-l-(2,3,5-tri-O-benzoyl-
p-D-ribofuranosyI)imidazo[4,5-b]quinoxalin-2-one (Sa)
was obtained in 88% yield as the only product. Deprotec-
tion of 8a with methanolic ammonia gave 6,7-dichloro-l-
(~-D-ribofuranosyl)imidazo[4,5-b]quinoxalin-2-one(8b).
The regiochemical assignment of 8b was accomplished by
using selective IH_13C decoupling." First, the three most
down-field carbon-13 peaks (153.64, 141.81 and 141.12
ppm) were identified as the three carbons on the imidazole
moiety since they are the only three aromatic carbons which
are not coupled to both H5 and H9. When the anomeric pro-
ton of 8h was irradiated, carbon-13 peaks at 153.64 ppm and
141.12 ppm weredecoup1ed which indicated that the ribosyl
moiety was attached a: the Nl position. The ~-cont1gura­
tion of 8b was confirmed by the NOE enhancement ob-
served between HI' and H4'.
Preparation of the target analogs (4) were approached
hydrogen-bonding potential as proposed for 2. Thus, these
compounds have the potential to interact with a biological
target in a unique manner.
4
2
CIX)):N....,NI }-x
o :Ow
HO OH
C'X1NXNI ')--X
o :o~
HO OH
3
CI:ceNI ')--x
~oW
HO OH
Synthesis of Imidazo[4,5-b]quinoxaline Ribonuclcosides J. Chin. Chern. Soc; Vol. 45, No.4, 1998 467
Scheme I Scheme 11
1) NHJ, 90 'C. 95%. 2) ca~nyl diimidazole. toluene, feflux 63%. 3) (a) BSA, CH3CN,
'.1.: (b} TSAR. TMSOTf, 50 C; 88%. 4) NHy'MeOH. r.t., 57%.
1
-
9
CIX)Ny NI ?-. ')-XCI~~
RO OR
I
-
8a
N HCI~:()=S
OYW
RO OR
" HCI~ :C>=oCI~N N
8Z0~
BzO OBz
2
--
4(88 R~Bz
8t1 R=H
CI~NyNH,
CI~N)l....NH,
6
3
-
CI~NyCI
CI~N)l....CI
5
CI=ONX~):::O
CI s, "'N ~
7
11POCI,. triazole, Et,N, r.l. 2) H,S, 79% frorn e. 3) cyclopropylamine or isop,opylamme.
4f NH" MeOH. 5) BnSr, NH.OH. S3%. 6) Aaney Ni. MeOH. reflux. 52%,
dazo[4,5-b]quinoxaline ribonucleosides (4c-f) were deter-
mined and compared to thecorresponding benzimidazole ri-
bonucleosides. Activity against HCMV and herpes simplex
virus type 1 (HSV-l) was determined using a plaque reduc-
tion assay for the former virus and an ELISA for the latter,
Two cytotoxicity assays were used which involved visual in-
spection of stationary human foreskin fibroblasts and grow-
ing KB cells (Table I). The benzylthio derivative 4c was
found to be five times more active than the corresponding
benzimidazole ribonucleoside Ic but also about 5 times
more cytotoxic. The cyclopropylamino derivative 4d like-
wise was somewhat more active against HCMV than the
benzimidazole ribonucleoside Id. The isopropylamino de-
rivative 4e was about as active and cytotoxic as 4d, COIll-
pared to the corresponding Nl isomer of imidazo[4,5-b]qui-
noline ribonucleosides, 4c and 4e showed essentially the
same activity as the imidazo[4,5-b]quinoline ribonu-
cleosides15whereas 4d was more effective. None of the imi-
dazo[4,5-b]quinoline nor the imidazo[4,5-b]quinoxaline ri-
bonucleosides, however, were as active against HCMV at
non-cytotoxic concentrations as was TCRB (Table I).
The antiviral activity of these imidazo[4,5-b]quinox-
aline rlbonucleosides demonstrated that a linear extension
of the aglycon of benzimidazole ribonucleosides with a
pyrazine spacer essentially retains some antiviral activity
by a functional group transformation at the 2-position of 8a.
When8a was treated with POCh/l,2,4-triazolelEbN2 1 in
acetonitrile at room temperature for 40 hours, Sa was. con-
verted into the 2-triazolyl derivative 9. Compound 9 was.
found to be quite unstable and was hydrolyzed to 8a during
silica gel chromatography and extraction. Therefore, com-
pound 9 was prepared and without isolation, it was con-
verted into 2-cyclopropylamino-6,7-dichloro-l-(2,3,5-tri-
O-benloyI-P-D-ribofuranosy1)imidazo[4,5 -b]quinoxaline
(10) and 6,7 -dichloro-2-isopropylamino-l-(2,3,5-tri-O-
benzoyl-~-D-ribofuranosyl)imidazo[4,5-b]quinoxaline(11)
by the addition of cyclopropylamine and isopropylamine,
respectively. Compound 10 and 11 were deprotected with
methanolic ammonia to afford 4d and 4e, respectively.
When compound 9 was treated with hydrogen sulfide, we
obtained 6,7 -dichloro-l-(2,3,5-tri-O-benzoyl-~-D-ribofura-
nosyI)imidazo[4,5-b]quinoxalin-2-tilione (12a). A removal
of the protecting groups furnished 6,7-dichloro-HP-D-ri-
bofuranosyl)imidazo[4,5-b]quinoxalin-2-thione (12b). 2-
Benzy Ithio-6,7-dichloro-l-tjl-D-ribofuranosyl)imidazo[4,5-
b]quinoxaline (4c) was prepared by the benzylation of 12b
with benzyl bromide, The DRB analog, 6,7-dichloro-l-(~­
D-ribofuranosyljimidazo]4,5-b]quinoxaline (40, was pre-
pared from 12b by Raney nickel desulfurization. The con-
version of a thio or alkylthio group to a chloro group by
chlorine has been found to be an efficient and facile method
for the generation of chloro substituted nuclcosidcs" and
been successfully used23 in the preparation of 2a and 3a.
However, attempts to convert the 2-thio group to a chloro
group on both I2a and 12b were found to be unsuccessful
due to the hydrolysis of the product during work-up. This
facile hydrolysis was most likely due to tile electron with-
drawing effect of the additional ring nitrogen.
Biology
The antiviral activity and cytotoxicity of the imi-
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Table 1. Antiviral Activity and Cytotoxicity of Benzimidazole and Imidazo[4,5-b]quinoxaIine
Ribonucleosides
Zhu etal.
C'i~1(yN'}-X'~~
HO 01-1
4
50% inhibitory concentration (11M)
antiviral activity" cytotoxicity"
substituent HCMV HSV-l b HFF cells KB cells
compound
no. X plaque ELISA visual growth
4c benzylthio 4.2 30 20 20
4d c-propy lam ina 32 >100 >100 90
4e i-propylamino 32 100 100 70
4f H 32 >100 45 >100
led benzylthio 22 25 100 >100
ld c-propylamino >100 20 >100 >100
It''',f H 42 30 24 36
la (TCRB)f Cl 2.9 102 238 210
ganciclovirf 7.7 1.8 >100 >100
• Plaque reduction assays were performed in duplicate wells using the Towne strain of HCMV as
described in the text. b Assayed by ELISA in quadruplicate wells. C Visual cytotoxicity scored on
HFF cells at time of HCMV plaque enumeration. Inhibition of KB cell growth was determined as
described in the text in quadruplicate wells. d Data for compound Ie published previously in refer-
ence 10. e Compound referred to as DRB by Tamm and coworkers. 12 f Data for DRB and TCRB
published previously in reference 9b. g Average of 88 experiments in which GCV was used as a
positive control.
compared to the benzimidazole nucleosides. For the ben-
zylthio and the isopropylamino derivatives, essentially the
same activity profile was observed between 2c and 4c, 2e
and 4e (in sharp contrast with 3c, 3e). This has implied that,
most likely, the additional binding through the N4 of these
analogs is crucial for their antiviral activity. On the other
hand, at least for the benzylthio and isopropylamino deriva-
tives, the conformational difference generated by the differ-
ent steric interaction between the aglycones and the ribosyl
moiety was minimal. We conclude, therefore, that the bind-
ing pocket on the target enzyme for the benzimidazole ri-
bonucleosides can tolerate the spacer between the imidazole
and benzene rings.
EXPERIMENTAL SECTION
General Chemical Procedures
Melting points were taken on a Thomas Hoover appa-
ratus and are uncorrected. Silica gel 60 230-400 mesh (E.
Merck, Darmstadt, West Germany) was used for chromatog-
raphy. Thin Layer Chromatography (TLC) was performed
on prescored SilicAR 7GF plates (Analtech, Newark, DE,
USA). Compounds were visualized by illumination under
UV light (254 nm). Evaporations were carried out under re-
duced pressure (water aspirator) with the bath temperature
below 40 ·C, unless specified otherwise. UV spectra were
performed on a Hewlett-Packard 8450-A UVNIS spectro-
photometer. Nuclear magnetic resonance (NMR) spectra
were determined at 360 MHz with a Broker WP360 SY. The
chemical shift values are expressed in 3 values relative to the
chemical shift of TMS or the solvent used. Elemental analy-
ses were performed by M-H-W Laboratories, Phoenix, AZ.
2,3- Diamlno-ri,7-dichloroquinoxaline (6)
2,3,6,7-Tetrachloroquinoxaline (5, 1.0 g, 3.67 mmol)
and liquid ammonia (20 mL) was heated in a steel bomb at
90 •C for 6·12 hours. The steel bomb was cooled to room
temperature and ammonia was allowed to evaporate. The
solid was triturated with water (30 ml.), collected by filtra-
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tion, washed with water and dried at 75°C to give 2,3-
diamino-6,7-dichloroquinoxaline (6, 0.83 g, 95.6%). Com-
pound 6 was dissolved in boiling DMF followed by the ad-
dition of ice water. The fine yellow crystals were collected,
washed with water and dried for analysis: Mp: > 260 0 C. 1H
NMR (DMSO-do); 07.45 (s, 2H), 6.98 (bs, 4H, DD ex-
changeable). Anal. Calcd for C8H6N4Ch: C, 41.94; H, 2.63;
N,24.45. Found: C, 42.00; H, 2.65; N, 24.46.
6,'-Dtchloroimidazo]4,5-bJquinoxalin-2-one (7)
2,3-Diamino-6,7-dichloroquinoxaline (6,0.226 g, 1.0
mrnol) and carbonyldiimidazole (0.195 g, 1.2 mmol) in 15
mL of freshly dried toluene were heated at reflux for 4
hours. The suspension was cooled to rOom temperature and
the solid was collected by filtration. The solid was stirred in
20 mL of water at room temperature for 2 hours, collected
by filtration, and dried under vacuum at 78 'C overnight to
give 6,7-dichloroimidazo[4,5-b]quinoxalill-2-one (7,0.159
g, 63%) as a slightly brown solid. Mp: decompose above
400°C. 'n NMR (DMSO-d6) : 0 12.123 (s, 2H), 8.048 (s,
2B). 13C NMR (DMSO-d6): S 155.19, 143.08, 137.88,
__ 128.34,128.00. UV [J..-max, nm (e)]: (MeOH) 350.6 (19100),
343.0 (14600), 334.8 (17200), 255.8 (17600), 220.6
(44700). Anal. Caled for C9I-4N40Ch: C, 42.35; H, 1.57;
N,.21.96. Found: C, 42.50; H, 1.60; N, 21.72.
6,7~Dichloro.l-(2,3,5-tri-O-benzoyl.~-D-ribofuranosyl)-
imidazo[4,S-b ]quinoxalin-2-one (Sa)
Bisttrimcthylsilyljacetamide (BSA, 1.7 mL, 6.75
mmo1) was added to a suspension of 6,7-dichloroimi-
dazo[4,5-b]quinoxaiin-2-one (7,0.182 g, 3.07 mmol) in dry
.... acetonitrile (l00 mL) and the suspension was stirred at
room temperature for 30 minutes. 1-O-Acctyl-2,3,5-tri.-O-
benzcyl-IfD-ribofuranose (1.62 g, 3.22 mmoI) was added
followed by trimethylsityl trifluoromethanesultonate
(TMSOTf, 1.3 mL, 6.1 mmol). After the reaction was
stirred at 50 ·C for 15 minutes, an additional quantity of
-TMSOTf (0.65 mL, 3.05 mmol) was added. The reaction
mixture was stirred at 50 0 C for an additional 10 minutes to
give a clear solution and then stirred at room temperature
overnight. The reaction solution was concentrated under re-
duced pressure to about 30 mL and then diluted with ethyl
acetate (200mL)_ The ethyl acetate solution was washed
with a saturated sodium bicarbonate solution (3 x 50 mL), a
saturated sodium chloride solution (50 mL) and dried over
anhydrous sodium sulfate. The solvent was evaporated, the
residue was subjected to silica gel flash Chromatography
and eluted with 0.5% methanol in chloroform. The appro-
priate fractions, as determined by TLC, were collected and
the solvent was evaporated to give 6,7-dichloro-I-(2,3,5-tri-
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O-benzoyl-p-D-ri bofuranosyIjimidazo]45-b]q uinoxalin-2-
one (8a, 1.875 g, 88%) as a white powder: Mp: 232-235 "C.
1H NMR (CDCh): 010.45 (s, lH), 8.040 (s, 1H), 7.906 (s,
2H), 8.055-7.283 (m, l5H), 6.659 (q, J == 3.76 Hz, J == 6.0
Hz, 1H), 6.43 (d, J == 3.6 Hz, IE), 6.418 (q, J == 6.3 Hz, J ==
8.0 Hz, IH), 4.898 (dd, J == 11.8 Hz, J == 3.5 Hz, lH),4.8]4
(Ill, lH), 4.726 (q, J == 11.8 Hz, J == 4.7 Hz, 1H). Anal. Calcd
for C35H24~08Ch; C, 60.09; 1-1,3.43; N, 8.01. Found: C,
60.31; H, 3.52; N, 7.84.
6,7-Dichloro-l-(~-D.ribofuranosyl)imidazo[4,S.b [quinox-
alin-2-one (8b)
6,7-Dichloro-1-(2,3,S-tri-O-benzoyl-P-D-ribofuranosyl)-
imidazo[4,5-b]quinoxalin-2-one (8a, 0.2 g) was stirred in a
saturated rnethanolic ammonia solution (100 mL) at room
temperature for 24 hours. The solvent was evaporated under
reduced pressure and the solid was triturated with hexane (3
x 30 mL). The hexane was decanted and the solid was dried
under 0.01 mmHg178 ·C for 24 hours and then recrystal-
lized from acetonitrile/methanol (10 mLl5 mL) to give 6,7·
dichloro-Lfji-Dvrlboturanosyljimidazo]4,5-b]quino xal in-
2-one (8b, 0.063 g, 57%) as a white solid. Mp: 216-2]8 "C.
lH NMR (DMSO-d6) : 5 12.670 (bs, IH), 8.189 (s. lH),
8.072 (s, 1H), 5.803 (d, J == 5.5 Hz, 1H), 4.279 (rn, lH),
3.896 (m, l H), 3.689 (m, lH), 3.537 (m, lH). Irradiation of
HI' (5.803 ppm) gave a 1.4% NOE enhancement of H4'
(3.896 ppm) while irradiation of H4' gave a 1.8% NOE en-
hancement of Hl ', l3C NMR (DMSO-d 6) : 5153.64,141.81,
l41.12, 137.69, 136.85, 129.08, 128.78, 128.11, 127.89,
85.76, 85.25, 70.65, 70.54, 61.96. UV [A-max, om (e)]:
(MeOH) 352.6 (20500),336.6 (17500), 256.6 (21200),
222.0 (44700). Anal. Caled for C 4HI2N40 sCh: C, 43.41; H,
3.10~ N, 14.4. Found: C, 43.25~ H, 3.17~ N, 14.03.
6,7-Dichloro-2-cyclopropylamino-l-(~.D-ribofuranosyl).
imidazo[4,S.b ]quinoxaiine (4d)
POCh (0.21 ml., 2.27 mmol) was added in one portion
to a solution of triazole (0.72 g, 10.4 mmol) in dry acetoni-
trile (23 mL) to give a white suspension. The suspension
was then cooled in an ice bath and triethyl amine (1.39 mL,
9.97 mmo!) was added dropwise. The suspension was
brought to room temperature and 6,7-dichloro-1-(2,3,5-tri-
O-benzoyl-f}-D-ribofuranosyl)imidazo[4,5-b]quilloxalin-2-
one (8a, 0.4 g, 0.57 mmol) was added. The suspension was
then stirred at room temperature for 40 hours to give a yel-
low suspension which was diluted with dry dichlo-
romethanc (17 mL) to give a clear dark-brown solution. Cy-
clopropylarnine (4 mL) was then added and the reaction so-
lution was stirred at room temperature for 4 hours. The sol-
vent was evaporated and the residue was subjected to silica
470 1. Chin. Chern. Soc.. Vol. 45, No.4, 1998
gel chromatography (5 x 7 em) with elution by chloroform.
The appropriate fractions, as determined by TLC, were col-
lected and the solvent was evaporated to give 6,7-dichloro-
2-cyc1opropy1ID1ino-l-(2,3,5-tri-O-benzoyl-P-D-ribofuranosyl)-
imidazo[4,5-b]quinoxaline (10,0.336 g, 80%) as a bright
yellow solid: Mp: 113-115 .c.
Compound 10 (OJ g) was stirred in a saturated
methanolic ammonia solution at room temperature for 24
hours. The solvent was evaporated and the residue was tri-
turated with hexane (2 x 30 mL). The hexane was decanted
and the solid was dried under 0.01 mmHg178 ·C for 24
hours. The solid was recrystallized from methanol to give
6,7 -dicbloro-2-cyclopropylamino-I-(p-D-ribofuranosyl)-
imidazo[4,5-b]quinoxaline (4d, 97 mg). The mother liquor
was subjected to silica gel chromatography (3 x 5 em) with
elution by I % methanol in chloroform. The appropriate
fractions were collected and the solvent was evaporated to
give an additional quantity of 4d (37 mg). The total yield of
4d was 77.3%: Mp: 196-198"C. lH NMR (DMSO-d6) 8
8.629 (bs, IH), 8.091 (s, IH), 8.081 (s, lH), 6.017 (d,J=7.6
Hz, IH), 5.985 (bs, lH), 5.457 (d, J =5.7 Hz, lH), 5.272 (d,
3.9, lH), 4.565 (q, J= 5.6, IH), 4.140 (m, lH), 4.039 (bs,
lH), 3.686 (m, 2H), 3.072 (m, lH), 0.825 (m, 2H), 0.685 (m,
2H). B C NMR (DMSO-d6) 0 161.09, 152.86, 144.28,
139.52, 136.03, 128.33, 128.09, 127.72, 127.25, 86.45,
85.93,71.21,70.64,61.46,25.44,6.25,5.91. UV [Am.x, 11m
(£)]: (MeOH) 366.6 (13500), 351.0 (12000), 268.0 (12800),
263.0 (12400), 227.2 (40200). Anal. Calcd for
CJ7HI7N504CIz: C, 47.89; H, 3.99; N, 16.43. Found: C,
47.65; H, 3.99; N, 16.35.
6,7-Dichloro-2-isopropylamino-l-(p-D-ribofuranosyl)irni-
dazo[4;5-b)quinoxaline (4e)
PQCh (0.16 mL, 1.7 mmol) was added in one portion
to a solution of 1,2,4-triazole (0.54 g, 7.8 mmol) in dry ace-
tonitrile (17 mL) to give a white suspension. The suspen-
sion was then cooled in an ice bath and triethylamine (1.04
mL, 7.5 mmol) was added dropwise. The suspension was
brought to room temperature and 6,7 -dichloro-l-(2,3,5-tri-
O-benzoyl- p-D-ribofuranosyl)imidazo[4,5 -b[quinoxalin- 2-
one (Sa, 0.3 g, 0.43 mmol) was added. The suspension was
then stirred at room temperature for 54 hours to give a yel-
low suspension. This suspension was diluted with dry di-
chloromethane (14 mL) to give a clear brown solution. Iso-
propylamine (4 mL) was then added and the reaction solu-
tion was stirred at room temperature for 3 hours. The sol-
vent was evaporated and the residue was dissolved in chlo-
roform and filtered through a short silica gel column to re-
move the salt. The silica gel bed was washed with 1%
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methanol in chloroform until the filtrate was devoid of UV
absorption. The filtrate was evaporated and the residue was
subjected to silica gel chromatography {S x 7 em) with elu-
tion by cbloroform. The appropriate fractions, as deter-
mined by TLC, were collected and the solvent was evapo-
rated to give 6,7-dichloro-2-isopropylarnino-l-(2,3,5 -tri-0-
benzoyl-p-D-ribofuranosyljirnidazo]4,5-b[quinoxaline (11,
0.22 g, 68%) as a yellow solid.
Compound 11 (0.202 g) was stirred in a saturated
methanolic ammonia solution (100 mL) at room tempera-
ture for 24 hours. The solvent was evaporated and the resi-
due was triturated with hexane (2 x 40 mL). The hexane
was decanted and the solid was dried under O.OJ mmHg178
·C for 24 hours. The solid was recrystallized from a mixture
of acetonitrile (10 mL) and ethanol (4 mL) to give 6,7-di-
chloro-S-Isopropylamino-I-tji-D-ribofuranosyl)imidazo-
[4,5-b]quinoxaline (4e, 92 mg). The mother liquor was sub-
jected to silica gel chromatography (3 x 5 em) wit.h elution
by I % methanol in chloroform. The appropriate fractions,
as determined by TLC, were collected and the solvent was
evaporated to give an additional quantity of 4e (8.7 mg).
The total yield of 4e was 81%: Mp: decompose above 240
'c. IH NMR (DMSO-d6) 3 8.415 (d, J"" 7.7 Hz, lH), 8.072
(s, l H), 8.051 (s, IH), 6.136 (d, J = 7.6 Hz, lH), 5.965 (bs,
IH), 5.468 (s, J == 5.8 Hz, lH), 5.279 (d, J =4.0 Hz, IH),
4.619 (q, J = 5.3 Hz, IH), 4.342 (m, IH), 4.166 (m, IH),
4.057 (bs, lH), 3.707 (bs, 2H), 1.281 (d, J =6.4 Hz, 6H).
13C NMR (DMSO-d6) 0159.49, 152.94, 144.47, 139.57,
136.00, 128.21, 127.96, 127.67, 127.01, 86.38, 85.92,
71.23; 70.61,61.50,45.19,22.14,22.05. UV (Amax, nm (£)1:
(MeOH) 368.0 (29600), 356.0 (28500), 270.0 (25400),
263.2 (26400), 225.8 (50800). Anal. Calcd for
C17Hl9Ns04Ch: C, 47.66; H, 4.44; N, 16.36. Found: C,
47.68; H, 4.45; N, 16.26.
6,7-Dichloro-1-(2,3,S-tri-O-benzoyl-f-n-r tbofuranosyf)-
imidazo[4,5-b[qulnoxelln-z-thlone (12a)
Phosphorus oxychloride (1.06 ml., 11.5 mmol) was
added to a solution of 1,2,4-lriazole (3.62 g, 52.4 mmol) in
dry acetonitrile (l10 mL) to give a white suspension. The
suspension was first cooled in an ice bath and triethyl amine
(6.94 mL, 49.8 mmol) was added dropwise. After stirring in
an ice bath for 5 minutes, the suspension was brought back
to room temperature and 6,7-dichloro-l-(2,3,5-tri-O-ben-
zoyl- ~-D-ri bofuranosyl)imidazo[4,5 -blq uinoxalin-2-one
(8a, 2.0 g, 2.9 mmol) was added in one portion. The suspen-
sion was then stirred at room temperature for 3 days to give
a yellow suspension. Hydrogen sulfide was bubbled into
the suspension for 5 minutes and the reaction flask was
Synthesis of Imidazo[4,5-b]quinoxaline Ribonucleosides
sealed with a rubber stopper and stirred at room temperature
for 30 minutes. The suspension was then concentrated to
about 20 mL and diluted with chloroform (500 mL). The
chloroform solution was washed sequentially with a satu-
rated sodium bicarbonate solution (2 x 200 ml.), water (4 x
300 ml.), a saturated sodium chloride solution, and dried
over anhydrous sodium sulfate. The solvent was evaporated
to give a yellow solid which was recrystallized from ethyl
acetate to give 6,7-dichloro-I-(2,3,5-tri-O-benzoyl-~-D-ri­
bofuranosyl)imidazo[4,5-b]quinoxalin-2-thione (12a, 1.35
g, 65.9%) as a yellow solid. The mother liquor was then
subjected to silica gel chromatography (3 x 7 em) and eluted
with 0.5% methanol in chloroform, The corresponding
fractions, as identified by TLC, were collected and evapo-
rated to dryness to give an additional quantity of 12a (0.27
g, 13.2%). The total yield was 79%: Mp: decompose above
290°C JH NMR (DMSO-d6) : <> 14.326 (bs, lH,), 8.255 (s,
IH), 7.981 (s, 1H), 7.943-7.250 (m, 15H), 6.945 (d, J = 2.9
HZ,lH), 6.654 (t, J:=6.6 Hz, IH), 6.562 (dd, J == 2.9 Hz, J =
5.7 Hz, lH), 4.912 (m, IH), 4.811 (dd, J == 3.14 Hz, J = 12.7
Hz, JH), 4.730 (dd, J == 4.23 Hz, J == 12.4 Hz, lH). Anal.
Calcd for C35H24N407SCh: C, 58.74; H, 3.36; N, 7.83.
Found: C, 58.62; H, 3.62; N, 7.89.
6,7-Dichl oro-I-(~-D-rihofuranosyl)imidazo[4,S·b[qulnox-
alin-z-thione (l2h)
6,7-Dichloro-1-(2,3,5-tri-O-benzoyI-~ -D-riboruranosyl)-
imidazo[4,5-b]quinoxalin-2-thione (12a, 0.4 g, 0.57 mmol)
was stirred with sodium rnethoxide (0.127 g, 2.4 mmoI) in
methanol (50 mL) at room temperature for 2 hours to give a
brown solution. Acetic acid (0.16 mL,2.8 mmol) was added
and the solution was stirred for 5 minutes. The solvent was
evaporated and the yellow solid was triturated with hexane
(3 x 40 mL). The hexane was decanted, and the solid was
dried under 0.Ql mm Hg!78 "C tor 24 hours and stirred in
water (50 ml.) at room temperature for 30 minutes. The
solid was collected by filtration and dried under vacuum.
The solid was then recrystallized from acetonitrile and etha-
nol 08 mLlI3 mL) to give 6,7-dich1oro-l-{~-D-ribofurano­
syl)imidazo[4,5-b]quinoxalin.2-tilione (12b, 0.189 g, 84%)
as a yellow solid: Mp: decompose above 240"C 'n NMR
(DMSO-d6) : s14.184 (bs, lH), 8.249 (s, IH), 8.137 (s, lB.),
6.445 (d, J = 5.0 Hz, IH), 5.322 (d, J = 5.0 Hz, lH), 5.159
(d, IH), 5.082 (m, lH), 4.810 (bs, an, 4.425 (m, IH), 3.932
(m, lH), 3.775 (m, lH), 3.600 (m, lH). J3C NMR (DMSO-
d6) : D 177.30, 142.58, 141.17, 138.11, 136.94, 130.Il,
129.75, 128.56, 128.28,88.76,85.41,70.52,70.37,61.92.
Anal. Caled for Ct4HJ2N404SCh 0.25 n.o. C, 41.23; H,
3.07; N, 13.74. Found: C, 41.08; H, 3.15; N, 13.36.
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2-Benzylthio-6,7-dichloro·l·(~-D.ribofuranosyl)imi­
dazo[4,S-b]quinoxaline (4c)
Benzyl bromide (0.36 mL, 3.0 mmol) was added to a
solution of 6,7-dichloro-l-tji-DvribofuranosyI)imidazo[4,5-
bJquinoxalin-2-lhione (Ub, 0.61 g, 1.51 mmot) in tile pres-
ence of concentrated ammonium hydroxide (about 2 mL) in
water (20 mL). The reaction mixture was stirred at room
temperature for 2 hours to give a slightly yellow suspension.
The solid was collected by filtration, washed with water and
dried under vacuum. The solid was then recrystallized from
n-butanol to give 2-benzylthio-6,7-dichloro-I-(~-D.ribo­
furanosyl)imidazo(4,5-b]quinoxaline (4c, 0.397 g, 53%) as
a slightly yellow solid: Mp: decompose above 220"C JH
NMR (DMSO-d6) : 0 8.397 (s, 1H), 8.273 (s, lH), 7.699-
7.282 (m, 5H), 5.837 (d, J == 6.2 Hz, lH), 5.533 (d, J == 5.9
Hz, lH), 5.311 (d,J = 5.0 Hz, 1H), 4.917 (t, J == 5.9 Hz, lH),
5.143 (q, J = 5.8 Hz, IH), 4.807 (m, 2H), 4.296 (m, J = 2.7
Hz, J == 5 Hz, nn, 3.969 (m, J =2.7 Hz, J =5.3 Hz, IH),
3.736 (m, IH), 3.597 (m, lH). !3C NMR (DMSO-d6) : 0
168.63, 150.60, 143.12, 138.99, 136.66, 136.38, 130.13,
129.29,128.61,128.34,127.76,88.95,86.24,70.63,70.42,
61.73,35.54. UV (Am." nrn (e)l: (MeOH) 372.6 (35600),
356.0 (26100), 269.6 (16700), 226.4 (54100), 204.0
(23500). Anal. Cal cd for C21H1SN404SCh: C, 51.12; H,
3.65; N, 11.36. Found: C, 50,96; H, 3.81; N, 1I.17.
6,7· Dichloro-l-(~-D-ribofuranosyl)imidazo[4,5 -b[quinox-
aline (41)
6,7-Dichloro-I-(~-D-ribofuranosyt)imidazo[4,5 -b]-
quinoxalin-2-thione (12b, 130 mg, 0.32 rnmol) was dis-
solved in methanol (60 mL) with heating. Raney nickel (2.6
g, wet paste) was added and the reaction mixture was heated
at reflux for one hour. The reaction mixture was cooled to
room temperature and filtered through Celite, The filtrate
wasevaporated under reducedpressure and the residue was
subjected to silica gel chromatography (5 x 5 cm) by elution
with lO% of methanol in chloroform. The appropriate trac-
tions were collected, as determined by TLe, and evaporated
under reduced pressure to give 6,7-dichloro-1-(~-D-ribo­
furanosyl)imidazo[4,5-b]quinoxaline (4f, 63 mg, 52.2%) as
a slightly brown solid: Mp: decompose above 180 "C. JH
NMR (DMSO-d6 69.487 (s, IH), 8.510 (s, IH), 8.457 (s,
IH), 6.125 (d, J == 4.5 Hz, nn, 5.587 (d, J = 5.4 Hz, lH),
5.287 (d,J=4.1 Hz, lH), 5.118 (t, J== 4.7 Hz, lH), 4.689 (q,
J = 5.0 Hz, lH), 4.253 (q, J = 4.8 Hz, 1H), 4.013 (m, lH),
3.740 (m, IH), 3.626 (m, 111). 13C NMR (DMSO-d6) ()
155.09, 151.20, 141.30, 139.41, 137.92, 131.26, 130.37,
129.81, 128.72,87.91,85.59,73.45,70.12,51.04. UV
[Am.u, nm (e)]: (MeOH) 354.0 (15100), 339.8 (15400),248.8
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(29700), 222.8 (46800). Anal. Calcd for C 4H12N40 4Ch: C,
45.28; H, 3.23; N, 15.09. Found: C, 44.90; H, 3.45; N,
14.83.
Cell Culture Procedures
The rouline growth and passage of KB, BSC-I and
EFF cells was performed in monolayer cultures using mini-
mal essential medium (MEM) with either Hanks salts
[MEM(H)] or Earle salts [MEM(E)] supplemented with
10%calf serum or 10% fetal bovine serum (HFF cells). The
sodium bicarbonate concentration was varied to meet the
buffering capacity required. Cells were passaged at 1:2 to
1:10 dilutions according to conventional procedures by us-
ing 0.05% trypsin plus 0.02% EDTA in a HEPES buffered
salt solution.
Virological Procedures
The Towne strain, plaque-purified isolate Po, of
HCMV was kindly provided by Dr. Mark Stinski, Univer-
sity of Iowa. The KOS strain of HSV-l was used in most ex-
perimcnts and was provided by Dr. Sandra K. Weller, Uni-
versity of Connecticut. Stock HCMV was prepared by in-
fecting HFF cells at a multiplicity of infeclion (m.o.i.) of <
0.01 plaque-forming units (p.f.u.) per cell as detailed pre-
viously.r' High titer HSV-I stocks were prepared by infect-
ing KB cells at an m.o.i. of < 0.1 also as detailed pre-
viously." Virus titers were determined using monolayer
cultures of HFF cells for HCMV and monolayer cultures of
BSC-l cells for HSV-I as described earlier. 24 Briefly, HFF
or BSC-I cells were planted as described above in 96-well
cluster dishes and incubated overnight at 37 •C. The next
day cultures were inoculated with HCMV or HSV-I and se-
rially diluted 1:3 across the remaining eleven columns of the
96-well plate. After virus adsorption the inoculum was re-
placed with fresh medium and cultures were incubated for
seven days for HCMV, two or three days for HSV-I.
Plaques were enumerated under 20-fold magnification in
wells having the dilution which gave 5 to 20 plaques per
well. Virus titers were calculated according to the following
formula: Titer (p.f.u.lmL) = number of plaques x 5 x 3";
where n represents the nth dilution of the virus used to infect
the well in which plaques were enumerated.
HCMV Plaque Reduction Assay
HFF cells in 24-well cluster dishes were infected with
approximately 100 p.f.u. of HCMV per em" cell sheet using
the procedures detailed above. Following virus adsorption,
compounds dissolved in growth medium were added to du-
plicate wells in four to eight selected concentrations. After
incubation at 37 ·C for 10 days, cell sheets were fixed,
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stained with crystal violet and microscopic plaques enumer-
ated as described above. Drug effects were calculated as a
percentage of reduction in number of plaques in the pres-
ence of each drug concentration compared to the number ob-
served in the absence of drug.
HSV·} ELISA
An ELISA was employed to detect HSV-l?S Ninety-
six-well cluster dishes were planted with 10,000 BSC-l
cells per well in 200 ul, per well of MEM(E) plus 10% calf
serum. After ovenight incubation at 37 ·C, selected drug
concentrations in quadruplicate and HSV-l at a concentra-
tion of 100 p.f.u.lwell were added. Following a three day in-
cubation at 37 ·C, medium was removed, plates were
blocked, rinsed, and horse radish peroxidase conjugated
rabbit anti-HSV-I antibody was added. Following removal
of the antibody containing solution, plates were rinsed, and
then developed by adding 150 ul. per well of a solution of
tetramethylbenzidine as substrate. The reaction was
stopped with H2S04 and absorbence was read at 450 and 570
nm. Drug effects were calculated as a percentage of the re-
duction in absorbence in the presence of each drug concen-
tration compared to absorbence obtained with virus in the
absence of drug.
Cytotoxicity Assays
Two different assays were used to examine cytotoxic-
ity of selected compounds by methods we have detailed pre-
viously. (i) Cytotoxicity produced in stationary HFF cells
was determined by microscopic inspection of cells not af-
fected by the virus used in plaque assays." (ii) The effect of
compounds during two population doublings of KB cells
was determined by crystal violet staining and spectro-
photometric quantitation of dye eluted from stained cells as
described earlier." Briefly, 96-well cluster dishes were
planted with KB cells at 3000-5000 cells per well. After
overnight incubation at 37 ·C, test compounds were added
in quadruplicate at six to eight concentrations. Plates were
incubated at 37°C for 48 hours in a CO2 incubator, rinsed,
fixed with 95% ethanol, and stained with 0.1% crystal vio-
let. Acidified ethanol was added and plates read at 570 nrn
in a spectrophotometer designed to read 96-well ELISA as-
say plates.
Data Analysis
Dose-response relationships were constructed by line-
arly regressing the percent inhibition of parameters derived
in the preceding sections against log drug concentrations.
Fifty-percent inhibitory concentrations (lCso) or IC90's were
calculated from the regression lines. Samples containing
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positive controls (acyclovir for HSV-l, ganciclovir for
HCMV, and 2-acetylpyridine thiosernicarbazone for cyto-
toxicity) were used in all assays.
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